🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "significant breakthrough" in the effort against drug-resistant strains of the bacteria, according to scientists.

An International Public Health Issue

The sexually transmitted infection are on the rise worldwide, with data suggesting over 82 million instances each year. Especially elevated rates are seen in Africa and countries within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune step in the reality of increasing worldwide cases, escalating drug resistance and the highly restricted therapeutic options currently available.”

Health officials are particularly alarmed about the rise in drug-resistant strains. The global health body has listed it as a "priority pathogen". Ongoing monitoring showed that resistance to key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Therapies Gain Approval

One new antibiotic, alternatively called Nuzolvence, was approved by the US FDA in December for combating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Researchers hope that focused deployment of this new drug will help hinder the spread of drug resistance.

Gepotidacin, developed by the pharmaceutical company GSK, was also approved in close succession. This treatment, which is additionally indicated for urinary tract infections, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin was the result of a unique collaborative effort for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to see it through.

“This authorization represents a huge turning point in the therapy of superbug gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Clinical Trial Results and Global Access

Based on results published in a major medical journal, the new drug eradicated over nine in ten of uncomplicated infections. This places it at an comparable level with the existing first-line therapy, which uses two antibiotics. The trial involved hundreds of patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the rights to make available and distribute the drug in a wide range of developing nations.

Clinicians treating patients have voiced optimism. Having a one-pill regimen of this kind is seen as a "game-changer" for managing the epidemic. This is deemed vital to lessen the impact of the infection for people and to prevent the spread of extremely resistant gonorrhoea worldwide.